tiprankstipranks
Trending News
More News >
Eckert & Ziegler Strahlen und Medizintechnik (DE:EUZ)
:EUZ
Advertisement

Eckert & Ziegler Strahlen und Medizintechnik (EUZ) AI Stock Analysis

Compare
16 Followers

Top Page

DE:EUZ

Eckert & Ziegler Strahlen und Medizintechnik

(LSE:EUZ)

Rating:78Outperform
Price Target:
€75.00
▲(10.54%Upside)
The overall score is driven by a strong financial performance and positive technical indicators. The company's financial health is solid, with impressive revenue growth and cash flow generation, which supports future growth. Technical analysis shows strong bullish momentum, although the stock is approaching overbought levels. The valuation appears stretched, with a high P/E ratio, but this is partially offset by the dividend yield.

Eckert & Ziegler Strahlen und Medizintechnik (EUZ) vs. iShares MSCI Germany ETF (EWG)

Eckert & Ziegler Strahlen und Medizintechnik Business Overview & Revenue Model

Company DescriptionEckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide. It operates in two segments, Medical and Isotope Products. The Medical segment offers small radioactive implants for the treatment of prostate cancer seeds; and eye application based on ruthenium-106 or iodine-125 for treating uveal melanoma. This segment also provides radiopharmaceuticals, laboratory equipment, hot cells, and services for radiopharmaceuticals, as well as eye applicators and prostate implants. The Isotope Products segment manufactures and sells radiation sources for imaging, measurement technology, material analysis, quality assurance, and environmental monitoring. This segment also offers calibration sources for medical imaging systems, and homeland security and radiometric level measurement products. The company was founded in 1992 and is headquartered in Berlin, Germany.
How the Company Makes MoneyEckert & Ziegler generates revenue through the sale of isotopic products and related services across its two primary sectors. In the medical sector, the company earns money by providing radioactive components used in radiopharmaceuticals, brachytherapy, and other medical imaging and treatment solutions. In the industrial sector, revenue is derived from the sale of products used in quality control, measurement, and testing processes. Additionally, the company offers services for the safe disposal of radioactive waste, which constitutes another significant revenue stream. Partnerships with healthcare institutions, research facilities, and industrial companies further bolster its earnings by expanding its market reach and product applications.

Eckert & Ziegler Strahlen und Medizintechnik Financial Statement Overview

Summary
Eckert & Ziegler Strahlen und Medizintechnik exhibits solid financial health with strong revenue growth, robust profitability margins, and a stable balance sheet. Cash flow generation is impressive, supporting future investment and growth opportunities. Continued focus on cost management and leveraging efficiencies will further enhance financial performance.
Income Statement
82
Very Positive
The company demonstrates strong revenue growth with a 20.22% increase from 2023 to 2024. Gross profit margin improved slightly, indicating good cost management. However, the net profit margin, while positive, suggests room for improvement in controlling expenses. EBIT and EBITDA margins remained robust, enhancing overall profitability.
Balance Sheet
75
Positive
The balance sheet is stable, with a solid equity ratio of 50.51% and a manageable debt-to-equity ratio of 0.25, indicating prudent financial leverage. Return on equity is healthy, reflecting efficient use of equity capital. The consistent growth in stockholders' equity further supports financial stability.
Cash Flow
78
Positive
Cash flow analysis shows a significant increase in free cash flow, with a 133.83% growth from 2023 to 2024, highlighting improved cash generation capabilities. The operating cash flow to net income ratio is strong, indicating effective conversion of income to cash. Free cash flow to net income ratio also underscores efficient cash management.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue295.85M246.09M222.26M180.44M176.14M
Gross Profit143.16M116.34M106.78M91.08M86.53M
EBITDA80.96M59.67M57.90M56.68M43.05M
Net Income33.28M26.30M29.28M34.53M21.29M
Balance Sheet
Total Assets442.40M439.36M416.84M347.73M292.00M
Cash, Cash Equivalents and Short-Term Investments118.36M68.00M82.70M95.02M88.61M
Total Debt55.34M56.30M49.59M26.97M20.40M
Total Liabilities217.18M215.27M203.21M155.20M143.08M
Stockholders Equity223.45M222.18M212.07M187.39M147.82M
Cash Flow
Free Cash Flow49.38M21.12M3.17M5.00M27.88M
Operating Cash Flow66.57M46.95M34.30M33.85M36.79M
Investing Cash Flow-16.59M-42.74M-41.04M-23.59M-13.35M
Financing Cash Flow-9.99M-9.28M-5.71M-6.06M-12.96M

Eckert & Ziegler Strahlen und Medizintechnik Technical Analysis

Technical Analysis Sentiment
Positive
Last Price67.85
Price Trends
50DMA
65.22
Positive
100DMA
60.50
Positive
200DMA
54.15
Positive
Market Momentum
MACD
0.35
Positive
RSI
54.49
Neutral
STOCH
58.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:EUZ, the sentiment is Positive. The current price of 67.85 is above the 20-day moving average (MA) of 66.28, above the 50-day MA of 65.22, and above the 200-day MA of 54.15, indicating a bullish trend. The MACD of 0.35 indicates Positive momentum. The RSI at 54.49 is Neutral, neither overbought nor oversold. The STOCH value of 58.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:EUZ.

Eckert & Ziegler Strahlen und Medizintechnik Peers Comparison

Overall Rating
UnderperformOutperform
Sector (66)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
€4.20B40.2717.48%0.75%15.89%14.62%
66
Neutral
€6.57B18.46-1.30%2.26%-0.22%-36.66%
€1.37B61.76-4.72%0.16%
€1.37B44.66-4.72%0.27%
€1.26B45.594.03%4.20%
€1.32B-20.51%
62
Neutral
€524.63M5.89-26.06%-10.32%-250.76%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
67.00
28.74
75.12%
GB:0N6Z
Biotest
41.20
-1.40
-3.29%
GB:0N70
Biotest
30.00
1.74
6.16%
GB:0MSD
CompuGroup Medical
23.86
7.76
48.20%
GB:0IRF
Evotec
7.44
-1.32
-15.07%
DE:FYB
Formycon AG
29.60
-23.30
-44.05%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 05, 2025